Welcome to our dedicated page for Nocturne Acquisition Corporation news (Ticker: MBTCR), a resource for investors and traders seeking the latest updates and insights on Nocturne Acquisition Corporation stock.
Nocturne Acquisition Corporation (symbol: MBTCR) is led by experienced technology and crypto operators, aiming to identify unique, public-ready opportunities. Leveraging deep industry expertise and a vast global network, the company seeks to partner with a crypto or AI tech firm that will drive the next wave of innovation.
The company recently announced a proposed business combination with Cognos Therapeutics, Inc., a medical technology company focusing on developing advanced devices for the treatment of neurological diseases. The merger is expected to bring forth innovative solutions to improve outcomes for patients.
Nocturne, formed in October 2020 as a blank check company, completed its IPO in April 2021. The company is guided by CEO Henry Monzon and CFO Ka Seng (Thomas) Ao, with a vision to facilitate groundbreaking advancements in the tech industry.
Nocturne Acquisition Corporation (NASDAQ: MBTC, MBTCU, MBTCR) announced a definitive business combination with Cognos Therapeutics, a company focused on innovative medical devices for neurological diseases. The transaction values Cognos at approximately $120 million and involves an all-stock deal where Cognos shareholders will receive Nocturne common stock valued at $10.30 each. The proposed combination, expected to close in the second or third quarter of 2023, aims to enhance Cognos' access to capital for advancing its SINNAIS™ Implantable Smart Pump, designed to improve drug delivery for brain cancer treatment.
FAQ
What is Nocturne Acquisition Corporation's core focus?
Who leads Nocturne Acquisition Corporation?
What recent announcement did Nocturne make regarding a business combination?
When was Nocturne Acquisition Corporation formed?
What is the goal of the proposed merger with Cognos Therapeutics, Inc.?
Who are the key executives at Nocturne Acquisition Corporation?
What industries does Nocturne Acquisition Corporation operate in?
What is the significance of Nocturne's deep industry expertise and global network?
What is the expected outcome of the business combination with Cognos Therapeutics, Inc.?
How can investors stay informed about Nocturne Acquisition Corporation's developments?
